Biotech · Private company
CRISPR Therapeutics AG
Track this companyFree. Adds CRISPR Therapeutics AG to your Dealase workspace and tells you when its record changes.
Clinical trials179 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- CTX110Phase 2 · B-cell MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- CTX112Phase 2 · Warm Autoimmune Hemolytic Anemia (WAIHA)ClinicalTrials.gov · fetched Nov 12, 2026
- CTX112Phase 2 · B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CTX340Phase 2 · HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- CTX112Phase 1 · SLE (Systemic Lupus)ClinicalTrials.gov · fetched Nov 12, 2026
- CTX120Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CTX130Phase 1 · T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CTX130Phase 1 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CTX131Phase 1 · T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CTX131Phase 1 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CTX310Phase 1 · CardiovascularClinicalTrials.gov · fetched Nov 12, 2026
- Non InterventionalHematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionPHASE1_PHASE2 · RECRUITING · started Aug 8, 2026ClinicalTrials.gov NCT07758634 · fetched Nov 12, 2026
- Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseasePHASE1_PHASE2 · RECRUITING · started Jul 17, 2026ClinicalTrials.gov NCT07549698 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseasePHASE1 · RECRUITING · started Mar 10, 2025ClinicalTrials.gov NCT06925542 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesPHASE1 · COMPLETED · started Aug 13, 2024ClinicalTrials.gov NCT06492304 · fetched Nov 12, 2026
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasPHASE1 · RECRUITING · started Jun 21, 2024ClinicalTrials.gov NCT07491172 · fetched Nov 12, 2026
- A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular TherapiesENROLLING_BY_INVITATION · started Nov 22, 2023ClinicalTrials.gov NCT06208878 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsPHASE1 · COMPLETED · started Mar 13, 2023ClinicalTrials.gov NCT05795595 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesPHASE1_PHASE2 · RECRUITING · started Mar 10, 2023ClinicalTrials.gov NCT05643742 · fetched Nov 12, 2026
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)PHASE3 · ACTIVE_NOT_RECRUITING · started May 3, 2022ClinicalTrials.gov NCT05356195 · fetched Nov 12, 2026
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)PHASE3 · ACTIVE_NOT_RECRUITING · started May 2, 2022ClinicalTrials.gov NCT05329649 · fetched Nov 12, 2026
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · ENROLLING_BY_INVITATION · started Jan 20, 2021ClinicalTrials.gov NCT04208529 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)PHASE1 · TERMINATED · started Jul 31, 2020ClinicalTrials.gov NCT04502446 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)PHASE1 · TERMINATED · started Jun 16, 2020ClinicalTrials.gov NCT04438083 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple MyelomaPHASE1 · TERMINATED · started Jan 22, 2020ClinicalTrials.gov NCT04244656 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)PHASE1_PHASE2 · TERMINATED · started Jul 22, 2019ClinicalTrials.gov NCT04035434 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseasePHASE2_PHASE3 · COMPLETED · started Nov 27, 2018ClinicalTrials.gov NCT03745287 · fetched Nov 12, 2026
- A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaPHASE2_PHASE3 · COMPLETED · started Sep 14, 2018ClinicalTrials.gov NCT03655678 · fetched Nov 12, 2026